Association of complete blood count parameters, d-dimer, and soluble P-selectin with risk of arterial thromboembolism in patients with cancer.
Aged
Arterial Occlusive Diseases
/ blood
Austria
/ epidemiology
Biomarkers
/ blood
Female
Fibrin Fibrinogen Degradation Products
/ analysis
Humans
Incidence
Leukocyte Count
Male
Middle Aged
Neoplasms
/ blood
Neutrophils
P-Selectin
/ blood
Predictive Value of Tests
Risk Assessment
Risk Factors
Thromboembolism
/ blood
arterial occlusive diseases
biomarkers
blood cell count
neoplasms
thrombosis
Journal
Journal of thrombosis and haemostasis : JTH
ISSN: 1538-7836
Titre abrégé: J Thromb Haemost
Pays: England
ID NLM: 101170508
Informations de publication
Date de publication:
08 2019
08 2019
Historique:
received:
01
03
2019
accepted:
03
05
2019
pubmed:
18
5
2019
medline:
15
7
2020
entrez:
18
5
2019
Statut:
ppublish
Résumé
Patients with cancer are at risk of developing arterial thromboembolism (ATE). With the prevalence of cancer and cardiovascular diseases on the rise, the identification of risk factors for ATE in patients with cancer is of emerging importance. As data on the association of potential biomarkers with risk of ATE in patients with cancer are scarce, we conducted a cohort study with the aim to identify blood-based biomarkers for ATE risk prediction in patients with cancer. Overall, 1883 patients with newly diagnosed cancer or progressive disease after complete or partial remission were included and followed for 2 years. Venous blood was drawn at study inclusion for measurement of complete blood count parameters, total cholesterol, d-dimer, and soluble P-selectin (sP-selectin) levels. The 2-year cumulative incidence of ATE was 2.5%. In univariable analysis, red cell distribution width (subdistribution hazard ratio (SHR) per doubling: 4.4, 95% CI: 1.4-14.1), leukocyte count (1.2, 1.1-1.5), neutrophil count (1.6, 1.1-2.3), and sP-selectin levels (1.9, 1.3-2.7) were associated with risk of ATE in patients with cancer; d-dimer was not associated with the risk of ATE (1.1, 0.9-1.4). After adjustment for age, sex, and smoking status the association prevailed for the neutrophil count (adjusted [adj.] SHR per doubling: 1.6, 1.1-2.4), and sP-selectin levels (1.8, 1.2-2.8). An elevated absolute neutrophil count and higher sP-selectin levels were associated with an increased risk of ATE in patients with cancer. Their role for predicting cancer-related ATE needs to be validated in further studies.
Sections du résumé
BACKGROUND
Patients with cancer are at risk of developing arterial thromboembolism (ATE). With the prevalence of cancer and cardiovascular diseases on the rise, the identification of risk factors for ATE in patients with cancer is of emerging importance.
OBJECTIVES
As data on the association of potential biomarkers with risk of ATE in patients with cancer are scarce, we conducted a cohort study with the aim to identify blood-based biomarkers for ATE risk prediction in patients with cancer.
PATIENTS/METHODS
Overall, 1883 patients with newly diagnosed cancer or progressive disease after complete or partial remission were included and followed for 2 years. Venous blood was drawn at study inclusion for measurement of complete blood count parameters, total cholesterol, d-dimer, and soluble P-selectin (sP-selectin) levels.
RESULTS
The 2-year cumulative incidence of ATE was 2.5%. In univariable analysis, red cell distribution width (subdistribution hazard ratio (SHR) per doubling: 4.4, 95% CI: 1.4-14.1), leukocyte count (1.2, 1.1-1.5), neutrophil count (1.6, 1.1-2.3), and sP-selectin levels (1.9, 1.3-2.7) were associated with risk of ATE in patients with cancer; d-dimer was not associated with the risk of ATE (1.1, 0.9-1.4). After adjustment for age, sex, and smoking status the association prevailed for the neutrophil count (adjusted [adj.] SHR per doubling: 1.6, 1.1-2.4), and sP-selectin levels (1.8, 1.2-2.8).
CONCLUSIONS
An elevated absolute neutrophil count and higher sP-selectin levels were associated with an increased risk of ATE in patients with cancer. Their role for predicting cancer-related ATE needs to be validated in further studies.
Identifiants
pubmed: 31099477
doi: 10.1111/jth.14484
pmc: PMC6771479
pii: S1538-7836(22)14306-0
doi:
Substances chimiques
Biomarkers
0
Fibrin Fibrinogen Degradation Products
0
P-Selectin
0
SELP protein, human
0
fibrin fragment D
0
Types de publication
Journal Article
Observational Study
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1335-1344Subventions
Organisme : Austrian Science Fund FWF
ID : F 5405
Pays : Austria
Informations de copyright
© 2019 The Authors. Journal of Thrombosis and Haemostasis published by Wiley Periodicals, Inc. on behalf of International Society on Thrombosis and Haemostasis.
Références
Atherosclerosis. 2015 May;240(1):3-9
pubmed: 25744700
Thromb Haemost. 2004 Jul;92(1):185-90
pubmed: 15213860
Eur Heart J. 1995 Nov;16 Suppl L:11-5
pubmed: 8869013
N Engl J Med. 2012 Feb 16;366(7):610-8
pubmed: 22335738
Thromb Haemost. 2007 Mar;97(3):400-7
pubmed: 17334507
Arterioscler Thromb Vasc Biol. 2009 Mar;29(3):332-6
pubmed: 19228607
J Am Coll Cardiol. 2017 Aug 22;70(8):926-938
pubmed: 28818202
J Am Heart Assoc. 2014 Aug 18;3(4):
pubmed: 25134681
Intern Emerg Med. 2014 Jun;9(4):359-64
pubmed: 24643640
J Thromb Haemost. 2018 Mar;16(3):508-518
pubmed: 29325226
Thromb Haemost. 2017 Jan 26;117(2):219-230
pubmed: 27882374
Blood. 2013 Sep 19;122(12):2011-8
pubmed: 23908470
Thromb Haemost. 2017 Jan 5;117(1):90-98
pubmed: 27761580
Haematologica. 2018 Sep;103(9):1549-1556
pubmed: 29794142
Blood. 2010 Dec 9;116(24):5377-82
pubmed: 20829374
Atherosclerosis. 2004 Jan;172(1):1-6
pubmed: 14709350
J Thromb Haemost. 2019 Aug;17(8):1335-1344
pubmed: 31099477
J Vasc Surg. 2011 Dec;54(6 Suppl):48S-55S
pubmed: 21890302
Clin Cancer Res. 2016 Jan 1;22(1):200-6
pubmed: 26302981
Nat Med. 2010 Aug;16(8):887-96
pubmed: 20676107
Blood. 2008 May 15;111(10):4902-7
pubmed: 18216292
Circulation. 2001 May 15;103(19):2323-7
pubmed: 11352877
J Thromb Thrombolysis. 2016 Jan;41(1):81-91
pubmed: 26780740
Arterioscler Thromb Vasc Biol. 1999 Mar;19(3):493-8
pubmed: 10073948
Cancer. 1950 Jan;3(1):32-5
pubmed: 15405679
J Am Heart Assoc. 2013 Jan 28;2(1):e003103
pubmed: 23525424
Platelets. 2018 Dec;29(8):771-772
pubmed: 30204046
J Vasc Surg. 2005 Aug;42(2):329-36
pubmed: 16102635
CA Cancer J Clin. 2014 Jul-Aug;64(4):252-71
pubmed: 24890451
J Thromb Haemost. 2015 Jan;13(1):17-22
pubmed: 25381723
J Cardiovasc Magn Reson. 2013 Jul 31;15:66
pubmed: 23902649
Thromb Res. 2012 Apr;129 Suppl 1:S6-9
pubmed: 22682135
Control Clin Trials. 1996 Aug;17(4):343-6
pubmed: 8889347
Arterioscler Thromb Vasc Biol. 2004 Oct;24(10):1957-62
pubmed: 15308549
Circulation. 2001 Jan 30;103(4):491-5
pubmed: 11157711
J Thorac Dis. 2015 Oct;7(10):E402-11
pubmed: 26623117
Blood. 2017 Mar 30;129(13):1831-1839
pubmed: 28073783
Glob Heart. 2013 Mar;8(1):25-33
pubmed: 25690261
Blood. 2008 Oct 1;112(7):2703-8
pubmed: 18539899
Oncologist. 2016 Feb;21(2):252-7
pubmed: 26764252
Blood. 2019 Feb 21;133(8):781-789
pubmed: 30578253
N Engl J Med. 1974 Jun 6;290(23):1275-8
pubmed: 4827627
Hamostaseologie. 2014;34(1):54-62
pubmed: 24305775
Circ Res. 2016 Sep 30;119(8):896-9
pubmed: 27688305
Thromb Res. 2014 May;133 Suppl 2:S39-43
pubmed: 24862144
Thromb Haemost. 2014 Apr 1;111(4):670-8
pubmed: 24306221
Clin Chem. 2007 Jul;53(7):1235-43
pubmed: 17510305
BMC Cancer. 2017 Aug 30;17(1):591
pubmed: 28854911
Cancer. 2005 Dec 15;104(12):2822-9
pubmed: 16284987
Lancet Haematol. 2018 Jul;5(7):e289-e298
pubmed: 29885940
Eur Heart J. 2003 Dec;24(24):2166-79
pubmed: 14659768
Circulation. 1994 Nov;90(5):2236-40
pubmed: 7955179
J Am Coll Cardiol. 2005 May 17;45(10):1638-43
pubmed: 15893180
PLoS One. 2015 May 07;10(5):e0124957
pubmed: 25950717
Blood. 2002 Jul 15;100(2):509-16
pubmed: 12091342
Thromb Haemost. 2013 Aug;110(2):233-43
pubmed: 23784703
J Thromb Haemost. 2015 Mar;13(3):390-7
pubmed: 25529107
Eur Heart J. 2017 Jun 7;38(22):1702-1704
pubmed: 30052884
Cardiol Res Pract. 2011 Mar 03;2011:394740
pubmed: 21403876
Thromb Res. 2016 Apr;140 Suppl 1:S176
pubmed: 27161690
Thromb Haemost. 2019 Feb;119(2):340-347
pubmed: 30593084
J Clin Oncol. 2009 Sep 1;27(25):4124-9
pubmed: 19636003
Platelets. 2016;27(1):80-5
pubmed: 25970326
Blood Coagul Fibrinolysis. 2001 Jan;12(1):43-50
pubmed: 11229826
Blood. 2016 Aug 11;128(6):753-62
pubmed: 27354721
Thromb Haemost. 2018 Nov;118(11):1875-1884
pubmed: 30296815